We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SEAT:NASDAQVivid Seats Inc. Analysis

Data as of 2026-06-11 - not real-time

$8.81

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Vivid Seats (SEAT) trades at $8.81, hovering just above its 20‑day SMA of 8.69 but still below the 200‑day SMA of 9.18, indicating short‑term momentum without long‑term confirmation. The RSI of 54.9 sits in neutral territory and the MACD histogram is negative, flagging a bearish signal despite a modest price bounce. Volatility is extreme at 96.9% over the past 30 days and beta is high at 1.79, underscoring a stock that swings sharply with market moves. Fundamentally, the company posts a gross margin of 68.4% yet an operating margin of -6.99% and a net profit margin of -82.2%, with negative EBITDA and free cash flow, reflecting a costly operating model. The balance sheet shows $402 M of debt against $144 M of cash, and a negative book value per share of -$8.68, amplifying balance‑sheet risk. Analysts’ price targets average $9.35‑$10.18, implying a modest upside of roughly 15% and the Fear & Greed Index is at 84.5 (Extreme Greed), suggesting market optimism may be overstated. Given the decreasing volume trend and a market cap under $100 M, liquidity is thin, further magnifying price swings. In this context, the stock appears undervalued relative to its target but carries substantial execution and financial risks.
The recommendation leans toward a cautious stance: short‑term pressure from bearish technicals and weak earnings suggests a sell bias, while the medium‑term outlook remains uncertain pending a turnaround in cash flow and margin improvement. Long‑term investors may consider a hold if they believe the company can leverage its marketplace platform and reduce debt, but the current risk profile—high volatility, negative cash generation, and a fragile balance sheet—warrants a prudent, watchful approach.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram
  • Price below 200‑day SMA
  • High 30‑day volatility

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Modest upside to analyst targets
  • Negative operating cash flow
  • Decreasing volume trend

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential platform monetization
  • High debt relative to cash
  • Persistent negative margins

Key Metrics & Analysis

Financial Health

Revenue Growth-23.30%
Profit Margin-82.25%
P/E Ratio-2.3
ROE-284.31%
ROA-3.32%
P/B Ratio-1.0
Op. Cash Flow$-20304000
Free Cash Flow$-10885250
Industry P/E16.9

Technical Analysis

TrendNeutral
RSI54.9
Support$7.68
Resistance$10.27
MA 20$8.69
MA 50$7.75
MA 200$9.18
MACDBearish
VolumeDecreasing
Fear & Greed Index84.54

Valuation

Target Price$10.18
Upside/Downside15.56%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.79
Volatility96.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.